Market Research Industry Today

Obsessive Compulsive Disorder Market Growth Anticipated by 2032 | Major Player: Biohaven Pharmaceuticals, expected to boost the market

DelveInsight’s “Obsessive Compulsive Disorder (Obsessive Compulsive Disorder) Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Published 11 December 2023

In the market landscape of Obsessive Compulsive Disorder, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled “Obsessive Compulsive Disorder Market Insights, Epidemiology and Market Forecast 2032” from DelveInsight. 

Progress in understanding disease mechanisms has led to the emergence of fresh diagnostic and therapeutic methodologies, paving the path for enhanced drug development. Positive growth in the market is anticipated, primarily driven by rising cases and the introduction of forthcoming therapies throughout the forecasted period.

The Obsessive Compulsive Disorder market report sheds light on Obsessive Compulsive Disorder current treatment practices, upcoming drugs in the Obsessive Compulsive Disorder pipeline, market shares of individual therapies, and the anticipated trajectory of the Obsessive Compulsive Disorder market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Obsessive Compulsive Disorder Market Growth

Increasing occurrences of Obsessive Compulsive Disorder are fueling research and therapy development, creating a conducive environment for the potential profitability of newer products.

Discover the Anticipated Evolution and Growth of the Market @ Obsessive Compulsive Disorder Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

  • Obsessive Compulsive Disorder Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Biohaven Pharmaceuticals, and others, are actively engaged in developing novel drugs for potential market entry.
  • Obsessive Compulsive Disorder Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Obsessive Compulsive Disorder. Therapies such as Troriluzole, and others are driving the Obsessive Compulsive Disorder market.

Obsessive Compulsive Disorder Market Dynamics

"The outcome regarding pipeline therapies' success in addressing relapse, treatment resistance, and side effects will significantly influence their impact on overall revenue generation."

Presently, there exists a dearth of clinical developments targeting obsessive-compulsive disorder (OCD). Following secondary searches across various databases, including NIH and EudraCT, it's evident that only a few companies are actively engaged in developing drug assets in the clinical phase. One such company investigating their asset in a clinical study is Biohaven Pharmaceuticals. The anticipated introduction of this emerging therapy is expected to positively impact the OCD market, with detailed therapy descriptions available in the report's emerging drugs section.

Troriluzole, a third-generation prodrug and new chemical entity, modulates glutamate, the most prevalent excitatory neurotransmitter in the human body. Its primary mode of action involves reducing synaptic levels of glutamate. Troriluzole enhances glutamate uptake from the synapse by boosting the expression and function of excitatory amino acid transporters located on glial cells, crucial in clearing glutamate from the synapse.

Compared to its active metabolite, troriluzole is optimized for improved bioavailability, pharmacokinetics, tolerability, and dosing. Based on its mechanism of action, preclinical data, and clinical studies, troriluzole holds potential for therapeutic benefits in neurological and neuropsychiatric disorders. The rationale for its use in OCD is supported by clinical data with its active metabolite, riluzole, in populations with OCD. This evidence is derived from open-label and placebo-controlled clinical trials, along with preclinical, genetic, and neuroimaging studies that implicate glutamatergic hyperactivity in the pathogenesis of OCD.

Presently, troriluzole is undergoing investigation in three ongoing Phase III and one Phase II/III clinical trials targeting adults with a primary diagnosis of OCD, as per the DSM-5 criteria.

Obsessive Compulsive Disorder Treatment Market

Obsessive-compulsive disorder (OCD) significantly impacts quality of life, leading to social isolation and imposing a considerable economic burden on society.

The treatment of OCD involves several components, commencing with establishing a therapeutic alliance with the patient and providing psychoeducation. This is followed by psychological and/or pharmacological approaches. For patients with treatment-resistant OCD, neuromodulation and neurosurgery may be considered. While alternative interventions show promise, they necessitate further evidence. Despite the existence of general management principles, tailoring treatments to individual needs is essential. For instance, some comorbid conditions (like depression) respond to primary OCD pharmacotherapies, while others (such as bipolar disorder) might require additional interventions. Similar pharmacotherapies and psychotherapies are utilized across different age groups, but adjustments are necessary when treating children and adolescents.

Cognitive-behavioral therapy (CBT) stands as the most evidence-based psychotherapy for OCD. Meta-analyses of randomized controlled trials consistently demonstrate significant improvement in OCD symptoms in adults and children undergoing CBT. CBT comprises cognitive reappraisal and behavioral intervention, with exposure and response prevention (ERP) being the specific psychological treatment for OCD. According to the International OCD Foundation, if outpatient ERP doesn't yield results, intensive care involving various sessions per week might be necessary, ranging from traditional outpatient to intensive outpatient treatments.

The most effective treatments for OCD are Cognitive Behavior Therapy (CBT) and/or medication, specifically a type of CBT called Exposure and Response Prevention (ERP) and/or serotonin reuptake inhibitors (SRIs). ERP is typically conducted by a licensed mental health professional in an outpatient setting, while medications are prescribed by licensed medical professionals and ideally coordinated with therapy.

OCD can be managed through pharmacotherapy, specialized psychotherapy, anatomically targeted treatments, or their combination. First-line treatments include cognitive-behavioral therapy and pharmacotherapy using selective serotonin reuptake inhibitors (SSRIs). However, a significant percentage of patients may not respond to these initial treatments. Even with optimized cognitive-behavioral therapy and augmented pharmacologic treatment, around 10% of patients remain treatment-resistant.

Treatment-resistant OCD is a significant cause of suffering and disability among individuals with mental disorders. Second-line treatments include augmentation with antipsychotics, electroconvulsive therapy, transcranial magnetic stimulation, and deep brain stimulation (DBS). Despite available treatments, the greatest unmet need for OCD patients and their families is accessing appropriate pharmacotherapy and/or cognitive-behavioral therapy. Issues related to treatment affordability, adequate medication dosing, information about treatment response, and relapse prevention also contribute to the problem.

Obsessive Compulsive Disorder Market Report Features

Geography Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Study Period: 2019-2032

Obsessive Compulsive Disorder Market Size: USD ~1000 Million in 2022

Key Obsessive Compulsive Disorder Companies: Biohaven Pharmaceuticals, and others.

Leading Obsessive Compulsive Disorder Companies and Emerging Drugs: Pioneering companies such as Biohaven Pharmaceuticals, among others, are actively developing novel drugs for potential entry into the Obsessive Compulsive Disorder market.

Obsessive Compulsive Disorder Therapeutic Landscape: Key therapies identified for Obsessive Compulsive Disorder treatment include Troriluzole, and more.

Obsessive Compulsive Disorder Overview:

Obsessive-Compulsive Disorder is a mental health condition characterized by repetitive, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) that a person feels compelled to perform. These obsessions and compulsions can interfere significantly with daily life, causing distress, anxiety, and disruptions in various aspects of functioning.

Obsessive Compulsive Disorder Symptoms:

Obsessions: These are persistent, unwanted thoughts, urges, or images that cause distress or anxiety. They can range from fears of contamination, fear of harming oneself or others, extreme need for symmetry or order, forbidden thoughts involving sex, religion, or aggression, and more.

Compulsions: These are repetitive behaviors or mental acts that a person feels driven to perform in response to an obsession or according to rigid rules. Compulsions are often aimed at reducing the distress caused by obsessions, but they are excessive and not realistically connected to the issue they aim to address. Compulsions can include excessive cleaning or handwashing, checking things repeatedly, counting, arranging things in a specific way, and other rituals.

Time-consuming: Obsessions and compulsions can consume a significant amount of time and interfere with daily activities, work, and relationships.

Interference with life: OCD can significantly impair a person's ability to function in various areas of life, causing distress and impacting relationships, work, and social activities.

Insight: Many individuals with OCD are aware that their obsessions and compulsions are irrational, but they feel unable to control them.

Obsessive Compulsive Disorder Causes:

The exact cause of OCD isn't entirely understood, but it's believed to involve a combination of genetic, neurological, behavioral, cognitive, and environmental factors. Imbalances in serotonin, a neurotransmitter, are also thought to play a role in the development of OCD.

Obsessive Compulsive Disorder Treatment:

Therapy: Cognitive-behavioral therapy (CBT), particularly exposure and response prevention (ERP), is considered the most effective form of psychotherapy for OCD. It involves gradually exposing the individual to their obsessions and preventing their typical compulsive responses.

Medications: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed medications for OCD. They help regulate serotonin levels in the brain and can reduce symptoms.

Self-help strategies: Mindfulness, stress-reduction techniques, and support groups can complement therapy and medication in managing OCD symptoms.

OCD is a chronic condition, but with proper treatment and support, individuals can learn to manage their symptoms effectively and lead fulfilling lives. Early recognition and intervention are key in managing the impact of OCD. Consulting a mental health professional is crucial for accurate diagnosis and appropriate treatment planning.

Key Facts Obsessive Compulsive Disorder Market Report:

  • Key players such as Biohaven Pharmaceuticals, and others are investigating its candidates for Obsessive Compulsive Disorder.
  • Obsessive Compulsive Disorder pipeline includes the major therapies such as Troriluzole, and others. 
  • In the US, out of the total diagnosed prevalent cases, ~684,800 cases are highest accounted cases for OCD in 30-44 age group , respectively in 2022. 
  • As per severity, severe cases of OCD made up ~1,091,000 cases whereas, mild OCD made up ~315,000 cases in the US in 2022.
  • Out of the total diagnosed prevalent cases in the 7MM, the US accounted for ~30% cases of OCD in 2022.

Obsessive Compulsive Disorder Epidemiology Segmentation:

“In the US, females accounted for more number of cases of OCD than the males in 2022.”

  • In 2022, the total prevalent cases of OCD were ~12,082,000 cases in the 7MM. These cases are expected to increase by 2032.
  • Spain accounted for ~600,000 total diagnosed cases of OCD in 2022, which formed approximately 7% of the total number of diagnosed cases of OCD in the 7MM.
  • In 2022, Italy accounted for ~87,000 cases of mild OCD and ~303,000 cases of severe OCD were observed for the severity-specific cases of OCD.

The Obsessive Compulsive Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Obsessive Compulsive Disorder

• Prevalent Cases of Obsessive Compulsive Disorder by severity

• Gender-specific Prevalence of Obsessive Compulsive Disorder

• Type-specific Prevalence of Obsessive Compulsive Disorder

• Age-specific Prevalence of Obsessive Compulsive Disorder

• Diagnosed Cases of Obsessive Compulsive Disorder

DelveInsight's comprehensive report provides a thorough exploration of the Obsessive Compulsive Disorder market, covering key Obsessive Compulsive Disorder players, emerging Obsessive Compulsive Disorder therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Obsessive Compulsive Disorder Market Outlook 2032

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Obsessive Compulsive Disorder market landscape.

  • Gain Competitive Edge in Indication Market : Understand the current landscape of the Obsessive Compulsive Disorder market, including the competitive environment, key companies developing drugs for Obsessive Compulsive Disorder , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
  • Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing tretment practices can helps in identifying gaps and opportunities within the Obsessive Compulsive Disorder market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Obsessive Compulsive Disorder. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
  • Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
  • Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Obsessive Compulsive Disorder market with clarity and purpose.

Related Reports:

Obsessive Compulsive Disorder Epidemiology Forecast

Obsessive Compulsive Disorder Epidemiology Forecast report delivers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Obsessive Compulsive Disorder Pipeline Insight

Obsessive Compulsive Disorder Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Obsessive Compulsive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 

Healthcare Consulting and Market Research Services by DelveInsight

Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European biosimilar landscape. Download Pharma Go-to-Market Case Study.

Trending Reports by DelveInsight

Functional Constipation Market

Lebers Hereditary Optic Neuropathy Market

Gastric Neuroendocrine Tumors Market

Immune Thrombocytopenic Purpura Market

Visceral Pain Associated With GI Disorders Market

Bullous Pemphigoid Market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market

Myocarditis Market

Recurrent Blood Clots Market

Zollinger-ellison Syndrome Market

Age-related Hearing Loss Medical Device Market

Heart Sounds Sensors Market

Hypoplastic Left Heart Syndrome Hlhs Market

Infectious Arthritis/Septic Arthritis Market

Plasmacytoma Market

Agoraphobia Market

Clinically Isolated Syndrome CIS Market

Fucosidosis Market

Major Depressive Disorder Market

Neuronal Ceroid-lipofuscinoses Market

Orthotic Devices Market

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Connect with DelveInsight:

LinkedIn | Facebook | Twitter

Contact Us:

Kritika Rehani

Team Lead, Marketing


Other Industry News

Ready to start publishing

Sign Up today!